Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Safety and Tolerability of Intradermal BOTOX® (OnabotulinumtoxinA) Purified Neurotoxin Complex in Participants With Facial Fine Lines

NCT04631588 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT04631588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04631588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Safety and Tolerability of Intradermal BOTOX® (OnabotulinumtoxinA) Purified Neurotoxin Complex in Participants With Facial Fine Lines
Lead sponsor
Allergan
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2020
Completion date
November 3, 2021
Enrollment
172 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

facial fine lines